Literature DB >> 2719952

Photoaffinity labeling of the monoamine transporter of bovine chromaffin granules and other monoamine storage vesicles using 7-azido-8-[125I]iodoketanserin.

M F Isambert1, B Gasnier, P M Laduron, J P Henry.   

Abstract

An iodinated azido derivative of ketanserin, 7-azido-8-[125I]iodoketanserin ( [125I]AZIK), has been used to label the monoamine transporter of bovine chromaffin granule membranes by the technique of photoaffinity labeling. In the dark, this derivative was found to bind reversibly to the membranes, with an equilibrium dissociation constant estimated to be 6 nM at 0 degrees C. As for ketanserin, binding occurred at the tetrabenazine site: (i) [125I]AZIK was displaced efficiently from its binding site by tetrabenazine, ketanserin, and 7-azidoketanserin, whereas serotonin, which is a substrate for the transporter but has a low affinity for tetrabenazine binding site, was a poor displacer; pipamperone and pyrilamine, two antagonists of respectively serotonin S2 and histamine H1 receptors, were inactive. (ii) 7-Azidoketanserin was a competitive inhibitor of [3H]dihydrotetrabenazine binding, and it inhibited the ATP-dependent uptake of serotonin by chromaffin granule ghosts. Irradiation of [125I]AZIK with long-wavelength UV light, followed by electrophoresis on sodium dodecyl sulfate/polyacrylamide gels and autoradiography, revealed irreversible labeling of a membrane component with an apparent molecular weight of 73,000. Tetrabenazine inhibited the labeling of this 73-kDa band in a manner parallel to the binding of [125I]AZIK in the dark. Such a labeling is totally compatible with previous results obtained through photolabeling with a tetrabenazine derivative or by target size analysis. Moreover, preliminary experiments showed that [125I]AZIK can label the tetrabenazine binding sites of various sources including rat striatum, rabbit platelets, human pheochromocytoma, and human adrenal medulla. Therefore, this molecule appears to be an excellent probe to label the monoamine transporter of different amine storage vesicles even without purification.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719952     DOI: 10.1021/bi00431a044

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells.

Authors:  M K Sievert; D S Thiriot; R H Edwards; A E Ruoho
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

Review 2.  The adrenal chromaffin granule: a model for large dense core vesicles of endocrine and nervous tissue.

Authors:  H Winkler
Journal:  J Anat       Date:  1993-10       Impact factor: 2.610

3.  SDS-resistant aggregation of membrane proteins: application to the purification of the vesicular monoamine transporter.

Authors:  C Sagné; M F Isambert; J P Henry; B Gasnier
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

Review 4.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 5.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

6.  Expression cloning of a reserpine-sensitive vesicular monoamine transporter.

Authors:  J D Erickson; L E Eiden; B J Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

7.  Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels.

Authors:  Michael K Sievert; Abdol R Hajipour; Arnold E Ruoho
Journal:  Anal Biochem       Date:  2007-05-03       Impact factor: 3.365

Review 8.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.